{"filings":[{"id":2033479,"accession_number":"0000078003-26-000094","cik":78003,"company_name":"PFIZER INC","ticker":"PFE","form_type":"8-K","filed_at":"2026-08-04T11:02:43+00:00","items":["2.02","9.01"],"status":"ready","headline":"Pfizer Q2 2026: Revenue $15.0B, raises FY guidance midpoint by $500M, reports net loss on $4.3B impairments","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q2 revenue $15.0B (+1% operational); launched/acquired products grew 18% operationally.","Reported net loss $248M ($0.04 LPS) from $4.3B impairments; adjusted EPS $0.77 flat YoY.","Raises FY2026 revenue guidance to $60.5-$62.5B (midpoint +$500M); reaffirms adjusted EPS $2.80-$3.00.","Announces additional $2.5B in productivity savings from 2027-2029; ongoing cost realignment program.","Pipeline: Lorbrena 7-yr PFS HR 0.19, Padcev MIBC approval, Litfulo vitiligo Phase 3 positive, sigvotatug vedotin miss."],"consensus_eps_estimate":0.6914,"consensus_eps_actual":0.43,"consensus_revenue_estimate":null,"consensus_revenue_actual":29484000000.0,"consensus_period":"2026-Q2","consensus_source":"xbrl+finnhub","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":149382425451.43365,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":1131596,"accession_number":"0000078003-26-000087","cik":78003,"company_name":"PFIZER INC","ticker":"PFE","form_type":"8-K","filed_at":"2026-06-18T17:17:22+00:00","items":["7.01","9.01"],"status":"ready","headline":"Pfizer reaffirms FY2026 guidance after CFO transition; revenue $59.5-$62.5B, adj. EPS $2.80-$3.00","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Reaffirms FY2026 revenue guidance of $59.5-$62.5 billion.","Reaffirms FY2026 adjusted diluted EPS guidance of $2.80-$3.00.","Reaffirmation follows CFO transition announcement on June 18, 2026.","Guidance originally introduced Dec 16, 2025 and reaffirmed on Q1 2026 earnings call May 5, 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":149382425451.43365,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":1120356,"accession_number":"0000078003-26-000085","cik":78003,"company_name":"PFIZER INC","ticker":"PFE","form_type":"8-K","filed_at":"2026-06-18T11:07:07+00:00","items":["5.02","9.01"],"status":"ready","headline":"Pfizer CFO Dave Denton to step down Aug 15; Cecile Guegan named interim CFO","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Dave Denton to step down as CFO effective August 15, 2026, for a consumer goods opportunity.","Departure not related to Pfizer's financial or operating results or any disagreements.","Cecile Guegan, SVP Finance, Global Biopharm Business, named interim CFO effective August 16.","Pfizer will conduct internal and external search for permanent CFO.","Guegan has over 20 years at Pfizer, led Seagen integration."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":149382425451.43365,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":98807,"accession_number":"0000078003-26-000053","cik":78003,"company_name":"PFIZER INC","ticker":"PFE","form_type":"8-K","filed_at":"2026-05-05T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Pfizer Q1 revenue $14.5B (+2% op); adj EPS $0.75 (-18%); reaffirms FY26 guidance","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $14.45B, up 2% operationally; ex-COVID products grew 7% op; launched/acquired products up 22% op.","Reported diluted EPS $0.47, adjusted $0.75 vs $0.92 in Q1 '25 (-18%).","Reaffirmed FY26 revenue guidance $59.5-62.5B and adj EPS $2.80-3.00.","Positive Phase 3 readouts for Elrexfio (RRMM), Padcev (MIBC), Talzenna+Xtandi, Lyme vaccine 73-75% efficacy.","Exited ViiV Healthcare for $1.875B; Vyndamax patent settlement extends to 2031; GLP-1 collaboration in China for ecnoglutide."],"consensus_eps_estimate":null,"consensus_eps_actual":0.47,"consensus_revenue_estimate":null,"consensus_revenue_actual":14451000000.0,"consensus_period":"2026-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":149382425451.43365,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":98806,"accession_number":"0000078003-26-000044","cik":78003,"company_name":"PFIZER INC","ticker":"PFE","form_type":"8-K","filed_at":"2026-04-27T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Pfizer annual meeting: all 12 directors elected, stock plan approved, independent chair proposal fails","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["All 12 director nominees elected; Joseph Echevarria received highest 'against' votes with 612.4M (16.4% of votes cast).","KPMG ratified as independent auditor for 2026 fiscal year with 93% of votes for (4.16B for, 322M against).","Pfizer 2019 Stock Plan amendment approved with 86.9% of votes cast (3.23B for, 305M against).","Advisory say-on-pay on 2026 executive compensation approved with 87.9% of votes cast (3.10B for, 424M against).","Shareholder independent chair proposal rejected; 28.8% of votes cast in favor (1.02B for, 2.51B against)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.15,"market_cap_usd":149382425451.43365,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":114479,"accession_number":"0000078003-26-000005","cik":78003,"company_name":"PFIZER INC","ticker":"PFE","form_type":"8-K","filed_at":"2026-02-03T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Pfizer reports FY2025 revenue $62.6B, adj. EPS $3.22; reaffirms FY2026 guidance","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Full-year 2025 revenue $62.6B (-2% operational); non-COVID portfolio +6% operational.","FY2025 reported diluted EPS $1.36; adjusted diluted EPS $3.22 (+4% YoY).","Q4 2025 revenue $17.6B (-1%); Q4 reported LPS ($0.29); adj. diluted EPS $0.66.","Completed Metsera acquisition (~$7B); ViiV stake sale for $1.875B; reaffirms FY2026 revenue guidance $59.5-62.5B, adj. EPS $2.80-3.00."],"consensus_eps_estimate":null,"consensus_eps_actual":1.36,"consensus_revenue_estimate":null,"consensus_revenue_actual":62579000000.0,"consensus_period":"2025-FY","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":149382425451.43365,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":130857,"accession_number":"0000078003-25-000167","cik":78003,"company_name":"PFIZER INC","ticker":"PFE","form_type":"8-K","filed_at":"2025-12-16T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Pfizer revises FY2025 revenue to ~$62B (from $61-64B), provides FY2026 EPS guidance $2.80-3.00","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revised FY2025 revenue guidance to ~$62.0B from prior $61-64B; reaffirmed adjusted diluted EPS $3.00-3.15.","FY2026 revenue guidance $59.5-62.5B; adjusted diluted EPS $2.80-3.00; tax rate ~15% vs ~11%.","COVID-19 product revenues ~$5.0B in 2026 (vs ~$6.5B in 2025); LOE impact ~$1.5B.","Adjusted SI&A $12.5-13.5B, R&D $10.5-11.5B in 2026; investing in PD-1 x VEGF bispecific and Metsera programs."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":149382425451.43365,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":130856,"accession_number":"0001193125-25-291406","cik":78003,"company_name":"PFIZER INC","ticker":"PFE","form_type":"8-K","filed_at":"2025-11-21T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Pfizer completes $6.0 billion offering of notes due 2027-2065","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Issued $500M Floating Rate Notes due 2027, $1B 3.875% Notes due 2027, $1B 4.200% Notes due 2030","Issued $1.25B 4.500% Notes due 2032, $1.25B 4.875% Notes due 2035, $500M 5.600% Notes due 2055","Issued $500M 5.700% Notes due 2065 for total aggregate principal of $6.0 billion","Underwriters include Citigroup, Deutsche Bank, J.P. Morgan, Mizuho Securities"],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":149382425451.43365,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":130855,"accession_number":"0000078003-25-000159","cik":78003,"company_name":"PFIZER INC","ticker":"PFE","form_type":"8-K","filed_at":"2025-11-13T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Pfizer completes $7B acquisition of Metsera, including contingent milestones up to $20.65/sh","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Enterprise value ~$7.0B; each Metsera share converted into $65.60 cash at closing.","Plus up to $20.65/sh in contingent value rights tied to three FDA/clinical milestones.","Milestones: Phase 3 start for MET-097i+MET-233i combo ($4.60/sh), FDA nod for monthly MET-097i ($6.40/sh), FDA nod for combo ($9.65/sh).","Acquisition aimed at bolstering Pfizer's obesity pipeline with GLP-1 receptor antagonist + amylin analog."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":149382425451.43365,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":130854,"accession_number":"0000078003-25-000149","cik":78003,"company_name":"PFIZER INC","ticker":"PFE","form_type":"8-K","filed_at":"2025-11-04T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Pfizer Q3 adj EPS $0.87 beat; raises FY adj EPS guidance to $3.00-$3.15; sues Novo Nordisk over Metsera","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q3 revenues $16.7B (-7% operational YoY); reported EPS $0.62, adj EPS $0.87.","Raises FY2025 adj diluted EPS guidance to $3.00-$3.15 from $2.90-$3.10; reaffirms revenue $61-64B.","Reached landmark agreement with U.S. government on drug pricing; sues Novo Nordisk for tortious interference over Metsera acquisition.","Inclacumab fails Phase 3 THRIVE-131 in sickle cell disease; $1.35B IPR&D charge for 3SBio deal.","Expects ~$7.2B net cost savings by 2027; no share repurchases planned; $7.3B dividends paid YTD."],"consensus_eps_estimate":null,"consensus_eps_actual":1.65,"consensus_revenue_estimate":null,"consensus_revenue_actual":45022000000.0,"consensus_period":"2025-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":149382425451.43365,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":147424,"accession_number":"0000078003-25-000136","cik":78003,"company_name":"PFIZER INC","ticker":"PFE","form_type":"8-K","filed_at":"2025-08-05T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Pfizer Q2 2025 revenue $14.7B (+10% YoY); raises FY adjusted EPS guidance to $2.90-$3.10","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Reported diluted EPS $0.51; adjusted diluted EPS $0.78, up 30% YoY.","FY 2025 revenue guidance reaffirmed at $61B-$64B; adjusted EPS guidance raised by $0.10 to $2.90-$3.10.","Vyndaqel family revenue up 21% operationally; Comirnaty +95%; Paxlovid +71%; Padcev +38%; Eliquis +6%.","Completed $1.25B upfront in-licensing of 3SBio's SSGJ-707; one-time ~$0.20 EPS impact in Q3.","On track for $7.2B net cost savings by end of 2027; capital allocation includes $4.9B dividends in H1."],"consensus_eps_estimate":null,"consensus_eps_actual":1.03,"consensus_revenue_estimate":null,"consensus_revenue_actual":28367000000.0,"consensus_period":"2025-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":149382425451.43365,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":166056,"accession_number":"0001193125-25-122480","cik":78003,"company_name":"PFIZER INC","ticker":"PFE","form_type":"8-K","filed_at":"2025-05-19T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Pfizer subsidiary completes €3.3B debt offering in four tranches","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Issued €750M 2.875% notes due 2029, €1B 3.250% notes due 2032, €750M 3.875% notes due 2037, €800M 4.250% notes due 2045.","Notes are fully and unconditionally guaranteed by Pfizer on a senior unsecured basis.","Offering completed on May 19, 2025 under existing shelf registration statement.","The debt raise adds €3.3B in long-term fixed-rate liabilities across maturities from 2029 to 2045."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":149382425451.43365,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":166055,"accession_number":"0000078003-25-000111","cik":78003,"company_name":"PFIZER INC","ticker":"PFE","form_type":"8-K","filed_at":"2025-04-29T23:59:59+00:00","items":["2.02","2.05","9.01"],"status":"ready","headline":"Pfizer Q1 revenues $13.7B (-8% YoY), adjusted EPS $0.92 (+12%); reaffirms FY2025 guidance","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Q1 revenues $13.7B, down 8% YoY; reported diluted EPS $0.52 (down 5%), adjusted diluted EPS $0.92 (up 12%).","Reaffirms FY2025 guidance: revenue $61-$64B, adjusted diluted EPS $2.80-$3.00, with no share buybacks anticipated.","Expands cost realignment: additional $1.2B net savings by 2027 (SI&A focus) plus $500M R&D reinvestment by 2026; one-time costs $1.6B and $600M respectively.","Paxlovid revenue fell $1.5B operationally (75% drop); Vyndaqel family grew 33% operationally; Comirnaty up 62% operationally.","Paid $2.4B in cash dividends ($0.43/shr) in Q1; gross leverage below previously stated target; $3.3B remaining buyback authority."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":149382425451.43365,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":166054,"accession_number":"0000078003-25-000109","cik":78003,"company_name":"PFIZER INC","ticker":"PFE","form_type":"8-K","filed_at":"2025-04-28T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Pfizer annual meeting results: all director nominees elected, say-on-pay passed with 54.7% approval","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["All 13 director nominees elected; highest support for Scott Gottlieb (3.50B for), lowest for Joseph Echevarria (3.17B for).","Ratification of KPMG as auditor for 2025 approved: 4.22B votes for (93.3% of votes cast).","Advisory say-on-pay approved with 54.7% support (1.95B for, 1.61B against); significant opposition noted.","Two shareholder proposals defeated: golden parachute vote (9.5% for) and religious discrimination report (2.0% for)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.15,"market_cap_usd":149382425451.43365,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":183580,"accession_number":"0000078003-25-000017","cik":78003,"company_name":"PFIZER INC","ticker":"PFE","form_type":"8-K","filed_at":"2025-02-04T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Pfizer Q4/FY2024 rev $63.6B (+7% op); adj EPS $3.11; reaffirms 2025 guidance","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["FY2024 revenues $63.6B (+7% operational); excluding COVID products, up 12% operationally.","FY2024 reported diluted EPS $1.41; adjusted diluted EPS $3.11. Q4 adjusted EPS $0.63.","Reaffirms FY2025 guidance: revenue $61-$64B, adjusted diluted EPS $2.80-$3.00.","On track for ~$4.5B net cost savings by end 2025; $1.5B from Manufacturing Optimization by 2027.","Positive Phase 3 BREAKWATER for Braftovi in mCRC; sold ~$3B Haleon stake; Boshoff named CSO."],"consensus_eps_estimate":null,"consensus_eps_actual":1.41,"consensus_revenue_estimate":null,"consensus_revenue_actual":63627000000.0,"consensus_period":"2024-FY","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":149382425451.43365,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":200164,"accession_number":"0000078003-24-000195","cik":78003,"company_name":"PFIZER INC","ticker":"PFE","form_type":"8-K","filed_at":"2024-12-17T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Pfizer provides 2025 revenue guidance $61-64B, adj. EPS $2.80-3.00","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Full-year 2025 revenue guidance range of $61.0 to $64.0 billion, with operational growth approximately flat to 5% year-over-year.","Full-year 2025 adjusted diluted EPS guidance range of $2.80 to $3.00, reflecting operational growth of 10% to 18%.","Achieved goal of $4.0 billion in net cost savings through 2024; expects an additional $500 million in savings in 2025.","First phase of manufacturing optimization program on track to deliver initial net cost savings in latter part of 2025.","Reaffirmed full-year 2024 guidance: revenue $61-64B, adjusted EPS $2.75-2.95."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":149382425451.43365,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":200163,"accession_number":"0000078003-24-000188","cik":78003,"company_name":"PFIZER INC","ticker":"PFE","form_type":"8-K","filed_at":"2024-10-29T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Pfizer Q3 revenue $17.7B (+32% YoY); raises FY 2024 guidance on revenue and EPS","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q3 2024 revenues of $17.7B, operational growth +32% YoY; ex-Paxlovid/Comirnaty revenue up 14% operationally.","Reported diluted EPS $0.78 vs. ($0.42) in Q3 2023; adjusted diluted EPS $1.06 vs. ($0.17).","Raised FY 2024 revenue guidance to $61-64B (from $59.5-62.5B) and adjusted EPS to $2.75-2.95 (from $2.45-2.65).","Paxlovid revenue $2.7B (+$2.5B YoY); Comirnaty revenue $1.4B (+9% operational).","Cost reduction program on track for at least $5.5B net savings; $4B expected by end of 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":1.34,"consensus_revenue_estimate":null,"consensus_revenue_actual":45864000000.0,"consensus_period":"2024-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":149382425451.43365,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":200162,"accession_number":"0000078003-24-000185","cik":78003,"company_name":"PFIZER INC","ticker":"PFE","form_type":"8-K","filed_at":"2024-10-15T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Pfizer elects former Vanguard CEO Tim Buckley to board of directors","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Mortimer J. Buckley elected to Pfizer Board effective Oct 10; appointed to Audit and Governance committees.","Buckley served as Vanguard Chairman & CEO from 2018 until retirement in 2024; previously CIO.","Board now has 14 directors, 13 of whom are independent."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":149382425451.43365,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":216183,"accession_number":"0000078003-24-000155","cik":78003,"company_name":"PFIZER INC","ticker":"PFE","form_type":"8-K","filed_at":"2024-07-30T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Pfizer Q2 adj EPS $0.60, revenue $13.3B; raises FY2024 guidance","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenues $13.3B, +2% YoY (+3% operational); non-COVID revenue grew 14% operationally.","Adjusted diluted EPS $0.60, vs $0.67 prior year; includes $1.3B one-time manufacturing optimization costs.","Raised FY2024 revenue guidance to $59.5-$62.5B (from $58.5-$61.5B) and adjusted EPS to $2.45-$2.65 (from $2.15-$2.35).","Launched Manufacturing Optimization Program targeting ~$1.5B cost savings by end of 2027; one-time costs ~$1.7B.","CSO Dr. Mikael Dolsten to depart; successor search underway."],"consensus_eps_estimate":null,"consensus_eps_actual":0.55,"consensus_revenue_estimate":null,"consensus_revenue_actual":28162000000.0,"consensus_period":"2024-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":149382425451.43365,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":216182,"accession_number":"0000078003-24-000144","cik":78003,"company_name":"PFIZER INC","ticker":"PFE","form_type":"8-K","filed_at":"2024-07-26T23:59:59+00:00","items":["5.02","8.01","9.01"],"status":"ready","headline":"Pfizer extends vesting and performance periods on 2022/2023 long-term equity awards for ~9,000 employees","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Up to 9,000 active employees eligible, including CEO Bourla, CFO Denton, and other named executives.","2022 and 2023 TSRUs can be extended for 2 years: settlement now Feb 2029 (2022 grants) and Feb 2030 (2023 grants).","2022 and 2023 PSAs can get a 2-year performance period extension, vesting in 2027 and 2028 respectively.","Modifications aim to restore retention value after COVID-related stock price decline reduced award incentive.","Election is voluntary via a forthcoming tender offer; all other award terms remain unchanged."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":149382425451.43365,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":216181,"accession_number":"0000078003-24-000130","cik":78003,"company_name":"PFIZER INC","ticker":"PFE","form_type":"8-K","filed_at":"2024-07-10T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Pfizer begins external search for successor to Chief Scientific Officer Mikael Dolsten","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["CSO and President of R&D Mikael Dolsten to step down after over 15 years; external search launched.","Dr. Dolsten will stay in current role until successor is appointed, at least through Feb 28, 2025.","No successor named; transition process formally announced on July 9, 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":149382425451.43365,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":216180,"accession_number":"0000078003-24-000127","cik":78003,"company_name":"PFIZER INC","ticker":"PFE","form_type":"8-K","filed_at":"2024-07-01T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Cyrus Taraporevala elected to Pfizer's Board of Directors effective June 27, 2024","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Taraporevala, former President & CEO of State Street Global Advisors (2017-2022), joins Board.","Appointed to Audit Committee and Compensation Committee immediately.","Also serves on boards of Shell plc and Bridgepoint Group plc.","Background includes roles at Fidelity, BNY Mellon, Legg Mason, Citigroup, and McKinsey."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":149382425451.43365,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":235717,"accession_number":"0000078003-24-000113","cik":78003,"company_name":"PFIZER INC","ticker":"PFE","form_type":"8-K","filed_at":"2024-05-22T23:59:59+00:00","items":["2.05"],"status":"ready","headline":"Pfizer launches multi-year COGS reduction program; targets $1.5B savings by 2027","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["First phase of cost-reduction program expected to deliver ~$1.5B savings by end of 2027.","One-time costs estimated at ~$1.7B, primarily severance and implementation costs.","Costs recorded mostly in 2024; cash outlays expected in 2025 and 2026.","Program includes operational efficiencies, network structure changes, and portfolio enhancements.","Savings realization expected to begin in 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":149382425451.43365,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":235716,"accession_number":"0000078003-24-000103","cik":78003,"company_name":"PFIZER INC","ticker":"PFE","form_type":"8-K","filed_at":"2024-05-01T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Pfizer Q1 revenue $14.9B (-20% YoY); adj. EPS $0.82; raises FY adj. EPS guidance","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q1 revenue $14.9B, operational decline 19% YoY; ex-COVID products grew 11% operationally.","Reported diluted EPS $0.55; adjusted diluted EPS $0.82 (includes $0.11 favorable Paxlovid return adjustment).","Full-year 2024 revenue guidance reaffirmed at $58.5-$61.5B; adjusted EPS guidance raised to $2.15-$2.35.","Cost realignment program on track to deliver at least $4 billion net cost savings by end of 2024.","Notable approvals: Beqvez (hemophilia B) FDA approval, Prevenar 20 (pediatrics) EU approval, Tivdak full FDA approval."],"consensus_eps_estimate":null,"consensus_eps_actual":0.55,"consensus_revenue_estimate":null,"consensus_revenue_actual":14879000000.0,"consensus_period":"2024-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":149382425451.43365,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":235715,"accession_number":"0000078003-24-000101","cik":78003,"company_name":"PFIZER INC","ticker":"PFE","form_type":"8-K","filed_at":"2024-04-29T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Pfizer shareholders elect all 12 board nominees, approve stock plan and say on pay at 2024 annual meeting","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["All 12 director nominees elected; Albert Bourla received 3.42B votes for (92.6% of votes cast).","Ratification of KPMG as auditor for 2024 approved with 4.32B votes for (93.9% of votes cast).","Amended and Restated 2019 Stock Plan approved with 3.41B votes for (92.5% of votes cast, excluding broker non-votes).","Advisory say-on-pay proposal approved with 3.36B votes for (91.4% of votes cast).","Shareholder proposals on independent board chair, political congruency report, and corporate contributions report all failed."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.15,"market_cap_usd":149382425451.43365,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":253479,"accession_number":"0000078003-24-000017","cik":78003,"company_name":"PFIZER INC","ticker":"PFE","form_type":"8-K","filed_at":"2024-01-30T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Pfizer posts FY2023 revenue $58.5B, adj EPS $1.84; reaffirms FY2024 guidance","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Full-year 2023 revenues $58.5B, down 41% operationally; reported diluted EPS $0.37, down 93%; adjusted diluted EPS $1.84, down 72%.","Q4 2023 revenues $14.2B, down 42% operationally; reported diluted LPS $(0.60), adjusted EPS $0.10.","Ex-COVID products grew 7% operationally in FY2023 (8% in Q4); Seagen acquisition closed Dec 2023 for $44B.","FY2024 revenue guidance $58.5-61.5B, adj EPS $2.05-2.25; expects $4B cost savings by end 2024.","No share repurchases planned in 2024; $9.2B dividends paid in FY2023."],"consensus_eps_estimate":null,"consensus_eps_actual":0.37,"consensus_revenue_estimate":null,"consensus_revenue_actual":58496000000.0,"consensus_period":"2023-FY","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":149382425451.43365,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":253478,"accession_number":"0000078003-24-000006","cik":78003,"company_name":"PFIZER INC","ticker":"PFE","form_type":"8-K","filed_at":"2024-01-10T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Pfizer warns shareholders of unsolicited mini-tender offer at below-market price","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["TRC Capital offers $27.35/share for up to 4M shares, 4.4% below Dec 27 close of $28.61.","Offer covers only ~0.071% of outstanding shares; Pfizer does not endorse it.","Stockholders who tendered can withdraw before offer expires Jan 30, 2024 at 12:01 a.m. ET.","SEC cautions that mini-tender offers may catch investors off guard; Pfizer advises no action."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":149382425451.43365,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":270945,"accession_number":"0001193125-23-294930","cik":78003,"company_name":"PFIZER INC","ticker":"PFE","form_type":"8-K","filed_at":"2023-12-14T23:59:59+00:00","items":["2.01","7.01","9.01"],"status":"ready","headline":"Pfizer completes $43B acquisition of Seagen at $229/share, expanding oncology portfolio","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Pfizer acquired Seagen for $229 per share in cash, total enterprise value of ~$43 billion.","Acquisition adds Seagen's four in-line ADC medicines (ADCETRIS, PADCEV, TIVDAK, TUKYSA) to Pfizer's oncology portfolio.","Pfizer's oncology pipeline doubles to 60 programs; now includes over 25 approved medicines across more than 40 indications.","To address FTC concerns, Pfizer irrevocably donates U.S. royalties from Bavencio (avelumab) to American Association for Cancer Research.","Pfizer expects oncology to be a significant growth driver and contribute to near- and long-term financial goals."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.95,"calibrated_materiality_score":0.95,"market_cap_usd":149382425451.43365,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":270940,"accession_number":"0001193125-23-295562","cik":78003,"company_name":"PFIZER INC","ticker":"PFE","form_type":"8-K/A","filed_at":"2023-12-14T23:59:59+00:00","items":["2.02","2.01","7.01","9.01"],"status":"ready","headline":"Pfizer completes $43B acquisition of Seagen; Seagen becomes wholly owned subsidiary","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Acquisition closed Dec 14, 2023; $229 per share in cash for total enterprise value approx. $43 billion.","Adds Seagen's four approved medicines (ADCETRIS, PADCEV, TIVDAK, TUKYSA) and ADC technology.","Pfizer's oncology pipeline doubled to 60 programs across multiple modalities.","To address FTC concerns, Pfizer irrevocably donated U.S. royalty rights from Bavencio (avelumab) to AACR.","Pfizer's oncology portfolio now includes over 25 approved medicines and biosimilars across >40 indications."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.9,"calibrated_materiality_score":0.9,"market_cap_usd":149382425451.43365,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":270944,"accession_number":"0000078003-23-000120","cik":78003,"company_name":"PFIZER INC","ticker":"PFE","form_type":"8-K","filed_at":"2023-12-13T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Pfizer guides FY2024 rev $58.5-61.5B, adj EPS $2.05-2.25; Seagen closing Dec 14","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["FY2024 revenue guidance $58.5-$61.5B; includes ~$8B from Comirnaty/Paxlovid and ~$3.1B from Seagen.","FY2024 adjusted diluted EPS guidance $2.05-$2.25; includes ~$0.40 dilution from Seagen.","Cost realignment program now expected to deliver at least $4.0B annual net savings by end 2024.","Excluding COVID products and Seagen, operational revenue growth 3%-5% YoY.","Seagen acquisition has received all regulatory approvals; closing expected Dec 14, 2023."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":149382425451.43365,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":270943,"accession_number":"0000078003-23-000118","cik":78003,"company_name":"PFIZER INC","ticker":"PFE","form_type":"8-K","filed_at":"2023-12-12T23:59:59+00:00","items":["5.02","7.01","9.01"],"status":"ready","headline":"Pfizer expects to close Seagen acquisition on Dec 14; all regulatory approvals received","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Expects to close Seagen acquisition on Dec 14, 2023 after receiving all required regulatory approvals.","Irrevocably donates U.S. royalties from Bavencio (avelumab) sales to AACR to address FTC concerns.","Creates Pfizer Oncology Division led by Chris Boshoff; splits non-oncology into U.S. and International divisions led by Aamir Malik and Alexandre de Germay.","Angela Hwang leaves role as Chief Commercial Officer; will serve as advisor to CEO during transition.","Plans analyst call on Dec 13 to discuss acquisition, new organization, and provide FY2024 financial guidance."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.9,"calibrated_materiality_score":0.9,"market_cap_usd":149382425451.43365,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":270942,"accession_number":"0000078003-23-000111","cik":78003,"company_name":"PFIZER INC","ticker":"PFE","form_type":"8-K","filed_at":"2023-10-31T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Pfizer Q3 revenue $13.2B (-42% YoY), adjusted LPS $(0.17) on $5.6B write-off; reaffirms FY guidance","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q3 revenues $13.2B, down 41% operationally; non-COVID products grew 10% operationally.","Reported diluted LPS $(0.42); adjusted diluted LPS $(0.17), including $5.6B non-cash inventory write-offs.","Reaffirms FY2023 guidance: revenue $58-61B, adjusted EPS $1.45-$1.65; expects $1B cost savings in 2023.","Comirnaty revenue down 70% operationally; Paxlovid down 97% operationally; Abrysvo contributed $375M.","Launched enterprise cost realignment program targeting at least $3.5B annual net savings by end of 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":0.96,"consensus_revenue_estimate":null,"consensus_revenue_actual":44247000000.0,"consensus_period":"2023-Q3","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":149382425451.43365,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":270941,"accession_number":"0000078003-23-000099","cik":78003,"company_name":"PFIZER INC","ticker":"PFE","form_type":"8-K","filed_at":"2023-10-13T23:59:59+00:00","items":["2.02","2.05","7.01","9.01"],"status":"ready","headline":"Pfizer cuts FY2023 revenue guide by $9B, records $5.5B COVID write-off, amends Paxlovid deal","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revises 2023 revenue to $58-61B (from $67-70B); Paxlovid revenues cut ~$7B including $4.2B reversal.","Records $5.5B non-cash Q3 charge for COVID inventory write-offs ($4.6B Paxlovid, $0.9B Comirnaty).","Amended U.S. Paxlovid deal: return ~7.9M EUA courses at year-end; commercial transition Jan 1, 2024.","Launches cost realignment program targeting $3.5B savings ($1B in 2023, $2.5B in 2024); ~$3B one-time costs.","Adjusted diluted EPS guidance cut to $1.45-$1.65 from $3.25-$3.45; non-COVID product growth reaffirmed at 6-8%."],"consensus_eps_estimate":null,"consensus_eps_actual":0.96,"consensus_revenue_estimate":null,"consensus_revenue_actual":44247000000.0,"consensus_period":"2023-Q3","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":1.0,"calibrated_materiality_score":1.0,"market_cap_usd":149382425451.43365,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":287844,"accession_number":"0000078003-23-000085","cik":78003,"company_name":"PFIZER INC","ticker":"PFE","form_type":"8-K","filed_at":"2023-08-01T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Pfizer Q2 revenues $12.7B (-54% YoY); narrows FY revenue guidance to $67-70B","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q2 reported diluted EPS $0.41 (-77% YoY); adjusted diluted EPS $0.67 (-67% YoY).","Comirnaty and Paxlovid combined revenue $1.6B; ex-COVID revenue grew 5% operationally.","Narrowed FY2023 revenue guidance to $67-70B (previously $67-71B); maintained adjusted EPS guidance $3.25-3.45.","Non-COVID operational growth expectation reduced to 6-8% from 7-9% due to label, ACIP recommendation, tornado damage.","Closed $31B debt offering to partly fund Seagen acquisition; transaction expected late 2023/early 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":1.38,"consensus_revenue_estimate":null,"consensus_revenue_actual":31015000000.0,"consensus_period":"2023-Q2","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":149382425451.43365,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":287843,"accession_number":"0000078003-23-000081","cik":78003,"company_name":"PFIZER INC","ticker":"PFE","form_type":"8-K","filed_at":"2023-07-27T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Pfizer restructures R&D, elevates Oncology as standalone unit; CDO William Pao departing Aug 15","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Pfizer restructures R&D, making Oncology a standalone unit; Dr. Chris Boshoff becomes Chief Oncology R&D Officer, EVP.","Dr. William Pao, Chief Development Officer, EVP, role eliminated; he will depart effective August 15, 2023.","Severance includes one year base salary and target bonus, two years welfare benefits, vesting of sign-on awards.","Reorganization driven by planned investment in Oncology, including proposed acquisition of Seagen Inc."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":149382425451.43365,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":308172,"accession_number":"0001193125-23-149364","cik":78003,"company_name":"PFIZER INC","ticker":"PFE","form_type":"8-K","filed_at":"2023-05-19T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Pfizer completes $31B multi-tranche note offering to fund Seagen acquisition","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Issued $31B aggregate principal across 8 tranches: 2025-2063 maturities, rates 4.45%-5.34%.","Notes fully and unconditionally guaranteed by Pfizer on a senior unsecured basis.","Special mandatory redemption at 101% if Seagen merger not consummated by Sep 19, 2024 or abandoned.","Net proceeds to finance portion of Seagen deal consideration and related fees; proceeds of 2033/2053 notes for general corporate purposes if redemption triggered.","Issued by wholly-owned Singapore subsidiary Pfizer Investment Enterprises Pte. Ltd."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":149382425451.43365,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":308171,"accession_number":"0001193125-23-144089","cik":78003,"company_name":"PFIZER INC","ticker":"PFE","form_type":"8-K","filed_at":"2023-05-15T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Pfizer and Seagen file HSR notification forms for merger","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["May 12, 2023: Pfizer and Seagen filed HSR Act notification forms with DOJ and FTC.","Closing subject to HSR waiting period expiration or termination.","If referred to EC under Article 4(5), EC approval becomes closing condition.","Merger announced March 12, 2023, with definitive agreement in place."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":149382425451.43365,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":308170,"accession_number":"0001628280-23-014759","cik":78003,"company_name":"PFIZER INC","ticker":"PFE","form_type":"8-K","filed_at":"2023-05-02T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Pfizer Q1 revenue falls 29% to $18.3B; adjusted EPS $1.23; reaffirms FY2023 guidance","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["First-quarter 2023 revenues $18.3B (down 29% YoY); reported diluted EPS $0.97, adjusted diluted EPS $1.23 (down 24% YoY).","Comirnaty revenues dropped 75% operationally; Paxlovid revenues increased by $2.8B; ex-COVID products grew 5% operationally.","FY2023 guidance reaffirmed: revenue $67-71B, adjusted EPS $3.25-3.45; midpoint implies ~31% operational revenue decline.","Proposed acquisition of Seagen (oncology ADC) expected to close late 2023 or early 2024; integration planning underway."],"consensus_eps_estimate":null,"consensus_eps_actual":0.97,"consensus_revenue_estimate":null,"consensus_revenue_actual":18282000000.0,"consensus_period":"2023-Q1","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":149382425451.43365,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":308169,"accession_number":"0001628280-23-014368","cik":78003,"company_name":"PFIZER INC","ticker":"PFE","form_type":"8-K","filed_at":"2023-05-01T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Pfizer announces 2023 annual meeting results; all director nominees elected","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["All 12 director nominees elected; Albert Bourla received 3.65B for, 208.7M against.","Ratification of KPMG as auditor approved: 4.48B for, 216M against.","Say-on-Pay approved (3.58B for); board adopts annual frequency for future votes.","All five shareholder proposals (e.g., independent chair, IP transfer) rejected.","Broker non-votes of ~822.8M on director elections and advisory items."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":149382425451.43365,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":327043,"accession_number":"0001193125-23-068538","cik":78003,"company_name":"PFIZER INC","ticker":"PFE","form_type":"8-K","filed_at":"2023-03-13T23:59:59+00:00","items":["1.01","7.01","8.01","9.01"],"status":"ready","headline":"Pfizer acquires Seagen for $229/share in $43B cash deal to boost oncology","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Acquisition of Seagen for $229 per share in cash; total enterprise value approximately $43 billion.","Seagen expected to generate ~$2.2B revenue in 2023 and contribute >$10B risk-adjusted revenue by 2030.","Pfizer to finance with $31B new long-term debt; deal expected to be neutral to slightly accretive to adjusted EPS in 3-4 years.","Transaction expected to close in late 2023 or early 2024, subject to shareholder vote and regulatory approvals.","Baker Bros. Advisors, holding significant Seagen shares, entered voting agreement to support the merger."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.95,"calibrated_materiality_score":0.95,"market_cap_usd":149382425451.43365,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":327042,"accession_number":"0000078003-23-000019","cik":78003,"company_name":"PFIZER INC","ticker":"PFE","form_type":"8-K","filed_at":"2023-02-21T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Pfizer relocates corporate headquarters to 66 Hudson Boulevard East, New York","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["New address effective February 21, 2023: 66 Hudson Boulevard East, New York, NY 10001-2192.","Telephone number remains (212) 733-2323; no other operational changes disclosed.","Relocation is a routine administrative move with no impact on business operations."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":149382425451.43365,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":327041,"accession_number":"0000078003-23-000004","cik":78003,"company_name":"PFIZER INC","ticker":"PFE","form_type":"8-K","filed_at":"2023-01-31T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Pfizer FY2022 revenue record $100.3B, adj. EPS $6.58; FY2023 guidance $67-71B rev, adj. EPS $3.25-3.45","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Full-year 2022 revenues $100.3B (record), up 23% YoY; reported EPS $5.47, adjusted EPS $6.58.","Q4 revenues $24.3B, reported EPS $0.87, adjusted EPS $1.14.","FY2023 revenue guidance $67-71B (down ~31%), adjusted EPS $3.25-3.45 (down ~49% operational).","Excluding COVID products, Pfizer expects 7-9% operational revenue growth in 2023.","Completed ~$26B in acquisitions in 2022 (Biohaven, Arena, GBT); $9B dividends, $2B share repurchases."],"consensus_eps_estimate":null,"consensus_eps_actual":5.47,"consensus_revenue_estimate":null,"consensus_revenue_actual":100330000000.0,"consensus_period":"2022-FY","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":149382425451.43365,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":344769,"accession_number":"0000078003-22-000107","cik":78003,"company_name":"PFIZER INC","ticker":"PFE","form_type":"8-K","filed_at":"2022-12-13T23:59:59+00:00","items":["5.03","9.01"],"status":"ready","headline":"Pfizer amends bylaws to require shareholder disclosure under SEC universal proxy rules","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Board amended bylaws on Dec 9, 2022, effective immediately.","Shareholders nominating directors must disclose intent to solicit proxies per Rule 14a-19.","Amendments incorporate technical changes to align with SEC's universal proxy rule.","No change to fiscal year; governance update only."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.2,"market_cap_usd":149382425451.43365,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":344768,"accession_number":"0000078003-22-000098","cik":78003,"company_name":"PFIZER INC","ticker":"PFE","form_type":"8-K","filed_at":"2022-11-01T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Pfizer Q3 revenue $22.6B (-6% YoY); Adj. EPS $1.78 (+40%); raises FY2022 guidance","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Reported diluted EPS $1.51 (+6%); Adjusted diluted EPS $1.78 (+40%) YoY.","Paxlovid contributed $7.5B in Q3; Comirnaty revenue guidance raised to ~$34B for 2022.","FY2022 revenue guidance raised to $99.5-102.0B; Adj. EPS guidance raised to $6.40-6.50.","Completed Biohaven ($12.8B) and GBT ($5.6B) acquisitions early Q4 2022.","Positive Phase 3 readouts for RSV vaccine, Prevnar 20 in pediatrics, and Talzenna/Xtandi combo."],"consensus_eps_estimate":null,"consensus_eps_actual":4.6,"consensus_revenue_estimate":null,"consensus_revenue_actual":76040000000.0,"consensus_period":"2022-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":149382425451.43365,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":361250,"accession_number":"0000078003-22-000091","cik":78003,"company_name":"PFIZER INC","ticker":"PFE","form_type":"8-K","filed_at":"2022-07-28T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Pfizer Q2 revenue $27.7B record; adj. EPS $2.04 (+92%); raises FY guidance $0.24","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q2 revenue $27.7B (+47% YoY, +53% operational); Paxlovid contributed $8.1B, Comirnaty +20% operationally.","Reported diluted EPS $1.73 (+77%); adjusted diluted EPS $2.04 (+92%), beating expectations.","Raised FY2022 adj. EPS guidance to $6.30-6.45 (lower end up $0.05); revenue reaffirmed $98-102B.","H1 capital: $4.5B dividends, $2B share buybacks; completed $6.3B Arena acquisition; announced $13.3B Biohaven deal."],"consensus_eps_estimate":null,"consensus_eps_actual":3.1,"consensus_revenue_estimate":null,"consensus_revenue_actual":53402000000.0,"consensus_period":"2022-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.9,"calibrated_materiality_score":0.9,"market_cap_usd":149382425451.43365,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":380500,"accession_number":"0001193125-22-145661","cik":78003,"company_name":"PFIZER INC","ticker":"PFE","form_type":"8-K","filed_at":"2022-05-10T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"Pfizer acquires Biohaven for $11.6B cash; gains migraine portfolio NURTEC ODT","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Total consideration ~$11.6B: $148.50/share cash + 0.5 share of New Biohaven per Biohaven share.","Acquires NURTEC ODT (rimegepant) approved for acute & preventive migraine, plus zavegepant & preclinical CGRP assets.","New Biohaven (SpinCo) retains non-CGRP pipeline, capitalized with $275M; eligible for tiered royalties on US sales >$5.25B.","Cash consideration represents ~33% premium to 3-month VWAP; closing expected early 2023, subject to approvals.","Pfizer also to repay Biohaven's $1.26B debt and redeem preferred shares at closing."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":149382425451.43365,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":380499,"accession_number":"0000078003-22-000068","cik":78003,"company_name":"PFIZER INC","ticker":"PFE","form_type":"8-K","filed_at":"2022-05-03T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Pfizer Q1 revenues $25.7B (+82%), EPS $1.62 adj.; reaffirms FY revenue $98-102B, adj. EPS $6.25-$6.45","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenues $25.7B up 82% operationally; ex-COVID products +2% operational growth.","Reported diluted EPS $1.37; Adjusted diluted EPS $1.62 (includes $0.05 negative from acquired IPR&D accounting change).","Full-year revenue guidance reaffirmed $98-$102B; adjusted EPS guidance revised to $6.25-$6.45 from $6.35-$6.55.","Comirnaty revenue guidance ~$32B; Paxlovid ~$22B; Chantix shipments remain paused globally due to impurity issue.","Pfizer repurchased 39.1M shares for $2B in March at avg $51.10; remaining authorization $3.3B."],"consensus_eps_estimate":null,"consensus_eps_actual":1.37,"consensus_revenue_estimate":null,"consensus_revenue_actual":25661000000.0,"consensus_period":"2022-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":149382425451.43365,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":380498,"accession_number":"0000078003-22-000066","cik":78003,"company_name":"PFIZER INC","ticker":"PFE","form_type":"8-K","filed_at":"2022-05-02T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Pfizer shareholders elect all 12 director nominees, defeat all four shareholder proposals at 2022 annual meeting","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["All 12 Board nominees elected, including CEO Albert Bourla and independent directors.","Ratification of KPMG as independent auditor for FY2022 approved with 4.44B votes for.","Advisory say-on-pay resolution for named executives approved with 3.51B votes for.","Four shareholder proposals (proxy access, political spending, IP transfer, anticompetitive risks) all defeated."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":149382425451.43365,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":380497,"accession_number":"0000078003-22-000062","cik":78003,"company_name":"PFIZER INC","ticker":"PFE","form_type":"8-K","filed_at":"2022-04-20T23:59:59+00:00","items":["2.02"],"status":"ready","headline":"Pfizer changes non-GAAP measure to include IPR&D costs; Q1 adj. income seen down ~$275M","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Starting Q1 2022, acquired IPR&D costs (upfront/milestone payments, asset acquisitions) included in Adjusted income; prior periods recast.","Expected Q1 2022 impact: Adjusted income reduced by ~$275M, Adjusted diluted EPS by ~$0.05.","Acquired IPR&D expenses will appear as a separate income-statement line item going forward.","FY guidance will include IPR&D costs for signed transactions through a defined date; excludes potential future deals.","Recast GAAP-to-non-GAAP reconciliations for 2020 and 2021 to be posted on or before April 30, 2022."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":149382425451.43365,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":380496,"accession_number":"0000078003-22-000057","cik":78003,"company_name":"PFIZER INC","ticker":"PFE","form_type":"8-K","filed_at":"2022-04-12T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Pfizer names David M. Denton as CFO effective May 2, 2022","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["David M. Denton named CFO, EVP effective May 2, 2022, succeeding Frank D'Amelio after 15-year career.","Compensation: $1.25M base salary, $1.25M target cash incentive (pro-rated for 2022).","One-time $5M cash payment (repayable if voluntary resignation within 1 year), RSUs valued at $3.25M, and $9.75M Supplemental Plan credit.","Denton brings 20+ years healthcare experience; previously CFO at Lowe's and CVS Health."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":149382425451.43365,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":"2022-04-12T23:59:59+00:00|380496"}